代谢综合征变体在恶性肿瘤进展中的作用。
The role of metabolic syndrome variant in the malignant tumors progression.
作者信息
Yunusova Natalia V, Kondakova Irina V, Kolomiets Larisa A, Afanas'ev Sergey G, Kishkina Anastasia Yu, Spirina Liudmila V
机构信息
Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Biochemistry Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia.
出版信息
Diabetes Metab Syndr. 2018 Sep;12(5):807-812. doi: 10.1016/j.dsx.2018.04.028. Epub 2018 Apr 17.
Metabolic syndrome (MS) is one of the leading risk factors for the development of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer). Currently, a drug-induced metabolic syndrome related with androgen deprivation therapy in patients with prostate cancer represents a serious medical problem. Not only MS, or its individual components, but MS variants with different levels of leptin, adiponectin, visfatin, resistin are associated with tumor invasion, metastasis and survival rates in patients with MS-associated malignancies.
代谢综合征（MS）是一些常见癌症（子宫内膜癌、绝经后乳腺癌、结直肠癌）发生的主要危险因素之一。目前，前列腺癌患者中与雄激素剥夺治疗相关的药物性代谢综合征是一个严重的医学问题。不仅MS或其各个组分，而且具有不同水平瘦素、脂联素、内脂素、抵抗素的MS变体都与MS相关恶性肿瘤患者的肿瘤侵袭、转移及生存率有关。
Zotero 插件